Skip to main content
Home

Top menu InfoLep

  • About InfoLep
  • News & Events
  • e-learning.infoNTD.org
Home

Main navigation InfoLep

  • Leprosy [5]
    • Global and Regional Leprosy Situation
    • WHO Global Leprosy Strategy
    • ILEP Strategy
    • World Leprosy Day
    • Leprosy journals
  • Key topics [7]
    • Leprosy and COVID-19
    • Diagnostic tests
    • Prevention of leprosy [2]
      • Interventions to reduce transmission: post-exposure prophylaxis (PEP) [3]
        • LPEP Programme
        • PEP++ project
        • PEP4LEP project
      • Interventions to reduce transmission: vaccines
    • Rehabilitation & prevention of disability [2]
      • Preventing leprosy-related disabilities in girls and boys
      • Self-care in leprosy
    • Leprosy Antibiotic Treatment
    • Stigma, discrimination & mental wellbeing [4]
      • World Leprosy Day 2022
      • Gender
      • Mental wellbeing
      • SARI Project
    • Bioarchaeology of leprosy
  • Toolkits [6]
    • Guides on Stigma and Mental Wellbeing [5]
      • Guide 1. What are health-related stigma and mental wellbeing? [8]
        • 1. What is stigma?
        • 2. Why does stigma exist?
        • 3. What are the causes of stigma?
        • 4. Who stigmatises?
        • 5. How does it feel to experience stigma?
        • 6. What are the effects of stigma?
        • 7. Effects of stigma and discrimination on mental wellbeing
        • Annex Guide 1
      • Guide 2. How to reduce the impact of stigma [7]
        • 1. From undetected disease to diagnosis to support
        • 2. Individual-level interventions
        • 3. Group-level interventions
        • 4. Family-level interventions
        • 5. Referral
        • 6. Further reading
        • Annexes Guide 2
      • Guide 3. How to reduce sources of stigma [6]
        • 1. Background to the design of a stigma-reduction intervention
        • 2. Identifying the sources of stigma
        • 3. Targeting an intervention
        • 4. Inclusion of affected persons and champions in interventions
        • 5. Interventions by source type
        • Annexes Guide 3
      • Guide 4. How to assess health-related stigma and mental wellbeing [9]
        • 1. What is the purpose of the assessment?
        • 2. What approach would best fit your purpose and context?
        • 3. Quantitative assessment methods
        • 4. Qualitative assessment methods
        • 5. Assessments using mixed methods
        • 6. Developing qualitative methods from scratch
        • 7. How do you conduct a stigma assessment?
        • 8. How to interpret and report your findings
        • Annexes Guide 4
      • Glossary
    • NTD Morbidity and Disability Toolkit [15]
      • CHIEF
      • Clinical Profile
      • EMIC affected persons
      • EMIC-CS Community Stigma
      • Participation Scale
      • Patient Health Questionnaire (PHQ-9)
      • 5-Question Stigma Indicators
      • Salsa Scale
      • SARI Stigma Scale
      • SDS Social Distance Scale
      • SRQ Self-reporting Questionnaire
      • Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS)
      • WGQ Washington Group Questions
      • WHODAS
      • WHOQOL-BREF
    • Perception Study Toolkit (PST)
    • Zero Leprosy Toolkit
    • CBM's Community Mental Health Good Practice Guides
    • GPZL & Infolep Factsheets
  • Online courses
  • Ocular DB

Top menu InfoLep

  • About InfoLep
  • News & Events
  • e-learning.infoNTD.org
Visit our e-learning platform
Search resources Search in Practical Materials, Publications, Organizations, Online Course and more
Publication

Safer and newer antimicrobial drugs for leprosy – time to test monthly ROM in an adequately powered randomised trial?

Lockwood DNJ, Penna GO, Lambert S, et al. Lepra. Leprosy Review. 2022; 93 (2) : 96-101.
Download PDF
Publication

Implementation of genetic screening test to reduce the incidence of dapsone hypersensitivity syndrome among patients with leprosy in Papua, Indonesia: a study protocol.

Krismawati H, Ferdiana A, Irwanto A, et al. BMJ open. 2022; 12 (5) : e057173.
Download PDF
Publication

[Late diagnosis nodular lepromatous leprosy from the Peruvian Amazon, with development of a type 2 reaction].

Villegas-Chiroque M, Maldonado-Gómez W, Espino-Saavedra W, et al. Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia. 2021; 38 (5) : 707-712.
Download PDF
Publication

Drug resistance in leprosy: an update following 70 years of chemotherapy.

Aubry A, Rosa SP, Chauffour A, et al. Infectious diseases now. 2022;
Download PDF
Publication

Zero leprosy: A united effort using existing & new tools but new perspectives

van Brakel WH. Wolters Kluwer. Indian Journal of Medical Research. 2022;
Download PDF
Publication

Epidemiological and clinical characterization of paraguayan patients with leprosy and household contacts before and after treatment with multi-drug therapy

Maiz GE, Rojas LE, Pereira JG, et al. Instituto de Investigaciones en Ciencias de la Salud. Anales de la Facultad de Ciencias Médicas (Asunción). 2022; 55 (1) : 49-62.
Download PDF
Publication

FARMACOTERAPIA APLICADA ÀS REAÇÕES IMUNOLÓGICAS DA HANSENÍASE

Da Silva PA, Peres JG, Freitas IKEV, et al. RECIMA21 - Revista Cientifica Multidisciplinar. RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218. 2022; 3 (4) : e341340.
Download PDF
Publication

The Experiences of Leprosy Clients Attending Self-Care Groups During Community-Based Rehabilitation for Fulfilling Their Health Needs

Susanto T, Bahtiar S, Deviantony F, et al. Indian Journal of Leprosy. 2022;
Download PDF
Publication

An Overview of Treatment Guidelines and Methods of Synthesis of Drugs Used in Leprosy Chemotherapy.

Pinheiro L, Borges J, Campos V, et al. Mini reviews in medicinal chemistry. 2022;
Publication

Innovative drug delivery systems for leprosy treatment.

da Rocha N, Barbosa E, de Araujo G, et al. Indian journal of dermatology, venereology and leprology. 2022;
Download PDF

Pagination

  • Previous page ‹‹
  • Page 24
  • Next page ››
Subscribe to Multi-drug therapy (MDT)

Quick links

  • Leprosy
  • Key topics
  • Toolbox
  • Publications

Support

  • Contact
  • Privacy statement
  • FAQ

Contact us

info@infolep.org

(+31) 20 595 0500

     

Stay up to date with the latest publications and news related to leprosy.

Subscribe to newsletter

Related websites:

© 2025 InfoNTD